Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ambu ASCHIX:AMBUBC 86 EV-to-EBITDA is 17.89 as of Aug. 03, 2026, which is 62% below its 10-year median of 47.34. GuruFocus rates CHIX:AMBUBC with a GF Score™ of 86/100 and a GF Value™ of kr119.75. Among 512 Medical Devices & Instruments companies, Ambu AS ranks worse than 59.77% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Ambu AS's enterprise value is kr18,836 Mil.
Ambu AS's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was kr1,053 Mil. Therefore, Ambu AS's EV-to-EBITDA for today is 17.89.
The historical rank and industry rank for Ambu AS's EV-to-EBITDA or its related term are showing as below:
CHIX:AMBUBc'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 15.09 Med: 47.34 Max: 159.86
Current: 17.89
During the past 13 years, the highest EV-to-EBITDA of Ambu AS was 159.86. The lowest was 15.09. And the median was 47.34.
CHIX:AMBUBc's EV-to-EBITDA is ranked worse than 59.77% of 512
companies
in the Medical Devices & Instruments industry
Industry Median: 14.37
vs CHIX:AMBUBc: 17.89
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ambu AS's share price for today is kr66.90.
Ambu AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr1.790.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Ambu AS's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:AMBUBC vs ABT, SYK, MDT: EV-to-EBITDA Comparison
For the Medical Devices subindustry, Ambu AS's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ambu AS EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Ambu AS's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Ambu AS's EV-to-EBITDA falls into.
Ambu AS's current Enterprise Value is kr18,836 Mil.
Ambu AS's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr1,053 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ambu AS (CHIX:AMBUBC) has a EV-to-EBITDA of 17.89 as of Aug. 03, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Ambu AS. This is 62% below median its historical median of 47.34. Over the past decade, Ambu AS's EV-to-EBITDA has ranged from 15.09 to 159.86. According to the industry distribution chart, Ambu AS ranks #306 out of 512 companies in the Medical Devices & Instruments industry, placing it in the top 59.8%.
Is Ambu AS's EV-to-EBITDA too high?
Ambu AS's current EV-to-EBITDA of 17.89 is 62% below median its 10-year median of 47.34. Over the past 10 years, this metric has ranged from a low of 15.09 to a high of 159.86. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.37. Ambu AS's value of 17.89 is 24.5% above this industry median. Based on the distribution chart, Ambu AS ranks #306 out of 512 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Ambu AS has a GF Score™ of 86/100, reflecting its overall financial health beyond just this single metric.
How does Ambu AS's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Ambu AS ranks #306 out of 512 companies for EV-to-EBITDA. This places Ambu AS in the lower half of its industry. The industry median EV-to-EBITDA is 14.37. Ambu AS's value of 17.89 is 24.5% above this benchmark. Historically, Ambu AS's own EV-to-EBITDA has ranged from 15.09 to 159.86 over the past decade. While the company's 10-year median is 47.34 vs. the industry median of 14.37, Ambu AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.37, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ambu AS's current EV-to-EBITDA of 17.89 is 24.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Ambu AS. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ambu AS's current EV-to-EBITDA is 17.89, which is 62% below median its own 10-year median of 47.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ambu AS stock overvalued right now?
Ambu AS (CHIX:AMBUBC) has a current EV-to-EBITDA of 17.89. The stock's GF Value™ is kr119.75, compared to a current price of kr66.90 — trading 44.1% below its estimated fair value. The current EV-to-EBITDA is 17.89, which is 62% below median its 10-year median of 47.34 and 24.5% above the Medical Devices & Instruments industry median of 14.37. Ambu AS's overall GF Score™ is 86/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Ambu AS (CHIX:AMBUBC), the current EV-to-EBITDA is 17.89 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ambu AS (CHIX:AMBUBC) Overvalued in 2026?
Based on GuruFocus' analysis, Ambu AS stock appears to be undervalued.
The current stock price of kr66.90 is trading 44.1% below its estimated GF Value™ of kr119.75.
Key valuation signals for CHIX:AMBUBC:
EV-to-EBITDA: 17.89 (62% below median its 10-year median of 47.34)
GF Value™: kr119.75 vs. price of kr66.90 (44.1% below fair value)
Industry Position: 24.5% above the Medical Devices & Instruments median (#306 of 512)
No single metric tells the full story. See the CHIX:AMBUBC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ambu AS provides medical technology solutions. The company's business consists of research and development of new solutions, which are then manufactured, marketed, and sold. It operates in two verticals: Endoscopy Solutions and Anesthesia & Patient Monitoring, with the majority of revenue being generated from the Endoscopy Solutions business. Geographical segments include North America, Europe, and the Rest of the World.
86GF Score
Get the complete analysis for CHIX:AMBUBC
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:AMBUBC has been successfully added to your 
